Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a promising biotechnology platform with a potential in-class CLDN18.2 bispecific antibody, givastomig, for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies. The company's strong immuno-oncology pipeline, including givastomig, uliledlimab, and ragistomig, and its successful combination therapy results with opdivo and chemotherapy in 1L HER2-negative metastatic gastric cancer patients, showcase its potential for future success. Additionally, NovaBridge's prudent financial management and commitment to givastomig's development and focus on US investors suggest a positive long-term outlook.

Bears say

NovaBridge Biosciences is poised for potential success with its strong pipeline of three clinical stage programs, including potential in-class bispecific antibody givastomig for the treatment of gastric cancer and other gastrointestinal malignancies. With FDA endorsement and improved tolerability, the company's givastomig is expected to integrate well into traditional chemo-IO backbone regimens, leading to potential accelerated timelines and bolstering global confidence in NovaBridge's restructured platform. This positive feedback and guidance from the FDA is expected to be a major leverage for the company in the future.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.